(S1 (S (S (NP (NP (NN Inhibition)) (PP (IN of) (NP (NP (ADJP (ADJP (JJ PDGF-stimulated)) (CC and) (ADJP (JJ matrix-mediated))) (NN proliferation)) (PP (IN of) (NP (JJ human) (JJ vascular) (NN smooth) (NN muscle) (NNS cells))))) (PP (IN by) (NP (NN SPARC)))) (VP (VBZ is) (ADJP (JJ independent) (PP (IN of) (NP (NP (NNS changes)) (PP (IN in) (NP (NP (NN cell) (NN shape)) (CC or) (NP (JJ cyclin-dependent) (NN kinase) (NNS inhibitors))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Interactions)) (PP (IN among) (NP (NP (NN growth) (NNS factors)) (, ,) (NP (NNS cells)) (, ,) (CC and) (NP (JJ extracellular) (NN matrix))))) (VP (VBP regulate) (NP (NN proliferation)) (PP (PP (IN during) (NP (JJ normal) (NN development))) (CC and) (PP (IN in) (NP (NP (NNS pathologies)) (PP (JJ such) (IN as) (NP (NN atherosclerosis)))))))) (. .)))
(S1 (S (S (NP (NP (NN SPARC)) (PRN (-LRB- -LRB-) (NP (NP (JJ secreted) (NN protein)) (, ,) (NP (ADJP (JJ acidic))) (, ,) (CC and) (NP (ADJP (JJ rich) (PP (IN in) (NP (NN cysteine)))))) (-RRB- -RRB-))) (VP (VBZ is) (NP (NP (DT a) (JJ matrix-associated) (NN glycoprotein)) (SBAR (WHNP (WDT that)) (S (VP (VBZ modulates) (NP (NP (DT the) (NP (NN adhesion)) (CC and) (NP (NN proliferation))) (PP (IN of) (NP (JJ vascular) (NNS cells)))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NN SPARC)) (VP (VBZ inhibits) (NP (NP (JJ human) (JJ arterial) (NN smooth) (NN muscle) (NN cell) (NN proliferation)) (VP (VBN stimulated) (PP (PP (IN by) (NP (JJ platelet-derived) (NN growth) (NN factor))) (CC or) (PP (IN by) (NP (NP (NN adhesion)) (PP (TO to) (NP (JJ monomeric) (NN type) (NN I) (NN collagen))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Binding) (NNS studies)) (PP (IN with) (NP (NP (NN SPARC)) (CC and) (NP (NN SPARC)) (NP (NNS peptides))))) (VP (VBP indicate) (NP (NP (ADJP (ADJP (JJ specific)) (CC and) (ADJP (JJ saturable))) (NN interaction)) (PP (IN with) (NP (JJ smooth) (NN muscle) (NNS cells))) (SBAR (WHNP (WDT that)) (S (VP (VBZ involves) (NP (NP (DT the) (JJ C-terminal) (JJ Ca2+-binding) (NN region)) (PP (IN of) (NP (DT the) (NN protein)))))))))) (. .)))
(S1 (S (S (NP (PRP We)) (ADVP (RB also)) (VP (VBP report) (SBAR (IN that) (S (NP (NN SPARC)) (VP (VBZ arrests) (NP (JJ monomeric) (JJ collagen-supported) (NN smooth) (NN muscle) (NN cell) (NN proliferation)) (PP (IN in) (NP (NP (DT the) (JJ late) (NN G1-phase)) (PP (IN of) (NP (NP (DT the) (NN cell) (NN cycle)) (PP (IN in) (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NP (DT an) (NN effect)) (PP (PP (IN on) (NP (NN cell) (NN shape))) (CC or) (PP (IN on) (NP (NP (NNS levels)) (PP (IN of) (NP (JJ cyclin-dependent) (NN kinase) (NNS inhibitors))))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Cyclin-dependent) (NN kinase-2) (NN activity)) (, ,) (NP (NP (NP (NN p107)) (CC and) (NP (NN cyclin) (NN A))) (NNS levels)) (, ,) (CC and) (NP (NN retinoblastoma) (NN protein) (NN phosphorylation))) (VP (VBP are) (VP (ADVP (RB markedly)) (VBN reduced) (PP (IN in) (NN response) (TO to) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NP (JJ exogenous) (NN SPARC)) (CC and/or) (NP (NP (NNS peptides)) (VP (VBN derived) (PP (IN from) (NP (NP (JJ specific) (NNS domains)) (PP (IN of) (NP (NN SPARC)))))))))))))) (. .)))
(S1 (S (S (ADVP (RB Thus)) (, ,) (NP (NP (NN SPARC)) (, ,) (VP (ADVP (RB previously)) (VBN characterized) (PP (IN as) (NP (NP (DT an) (NN inhibitor)) (PP (IN of) (NP (NP (JJ platelet-derived) (NN growth) (NN factor)) (VP (VBG binding) (PP (TO to) (NP (PRP$ its) (NN receptor))))))))) (, ,)) (ADVP (RB also)) (VP (VBZ antagonizes) (NP (NP (JJ smooth) (NN muscle) (NN cell) (NN proliferation)) (VP (VBN mediated) (PP (IN by) (NP (NP (JJ monomeric) (NN collagen)) (PP (IN at) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (JJ cyclin-dependent) (NN kinase-2) (NN activity))))))))))) (. .)))
